Share on StockTwits

Haemonetics (NYSE:HAE) Director Ronald Merriman sold 13,602 shares of the stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $35.76, for a total value of $486,407.52. Following the completion of the sale, the director now directly owns 12,105 shares of the company’s stock, valued at approximately $432,875. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Haemonetics (NYSE:HAE) traded down 0.22% during mid-day trading on Thursday, hitting $36.34. 32,582 shares of the company’s stock traded hands. Haemonetics has a 1-year low of $29.86 and a 1-year high of $44.20. The stock has a 50-day moving average of $35.59 and a 200-day moving average of $35.04. The company has a market cap of $1.869 billion and a P/E ratio of 48.82.

Haemonetics (NYSE:HAE) last released its earnings data on Wednesday, July 30th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.02. The company had revenue of $224.49 million for the quarter, compared to the consensus estimate of $215.85 million. During the same quarter in the prior year, the company posted $0.46 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. Analysts expect that Haemonetics will post $1.90 EPS for the current fiscal year.

A number of analysts have recently weighed in on HAE shares. Analysts at Jefferies Group raised their price target on shares of Haemonetics from $38.00 to $41.00 in a research note on Thursday, July 31st. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $40.33.

Haemonetics Corporation is a healthcare company engaged in providing blood management solutions to its customers.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.